Redhill Biopharma (RDHL)
(Delayed Data from NSDQ)
$8.21 USD
-0.29 (-3.36%)
Updated Oct 17, 2024 03:52 PM ET
After-Market: $8.16 -0.05 (-0.55%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$8.21 USD
-0.29 (-3.36%)
Updated Oct 17, 2024 03:52 PM ET
After-Market: $8.16 -0.05 (-0.55%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
RedHill Biopharma (RDHL) Up on New Patent for COVID-19 Candidate
by Zacks Equity Research
RedHill Biopharma (RDHL) receives a new patent from the United States Patent and Trademark Office for its investigational COVID-19 candidate, opaganib, in COVID-19 patients with pneumonia. Stock up.
RedHill (RDHL) Up on Orphan Drug Tag for NTM Disease Drug
by Zacks Equity Research
RedHill's (RDHL) RHB-204 gets Orphan Drug designation from the European Commission for the treatment of nontuberculous mycobacteria (NTM) disease
Redhill Biopharma Ltd. (RDHL) Could Find Support Soon, Here's Why You Should Buy the Stock Now
by Zacks Equity Research
Redhill Biopharma Ltd. (RDHL) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
RedHill (RDHL) COVID Pneumonia Drug Meets Study Goal, Stock Up
by Zacks Equity Research
Redhill's (RDHL) opaganib achieves a significant reduction in mortality in hospitalized patients with severe COVID-19 pneumonia based on new data from the phase II/III study.
RedHill (RDHL) Down on Unsatisfactory Data From COVID-19 Study
by Zacks Equity Research
RedHill (RDHL) posts preliminary top-line data from a phase II/III study evaluating opaganib in hospitalized patients with severe COVID-19 pneumonia. Stocks falls as the study fails to achieve its goal.
RedHill's (RDHL) Opaganib Effective Against Kidney Fibrosis
by Zacks Equity Research
Opaganib, Redhill's (RDHL) candidate for COVID-19, achieves a significant reduction in kidney fibrosis in preclinical studies.
Biotech Stock Roundup: REGN Gives Study Update, INCY Wins Drug Approval & More
by Zacks Equity Research
Regulatory and pipeline updates from Regeneron (REGN) and Incyte (INCY), among others, have been in focus in the biotech industry over the past week.
Strength Seen in Redhill Biopharma Ltd. (RDHL): Can Its 5.4% Jump Turn into More Strength?
by Zacks Equity Research
Redhill Biopharma Ltd. (RDHL) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
RedHill (RDHL) Doses First Patient in Phase II/III COVID-19 Study
by Zacks Equity Research
RedHill (RDHL) doses first patient in phase II/III study of orally-administered RHB-107 (upamostat), an investigational new drug for patients with symptomatic COVID-19 who do not require hospital care.
RedHill's (RDHL) RHB-204 Gets FDA Fast Track Designation
by Zacks Equity Research
RedHill (RDHL) gets Fast Track status from the FDA for the treatment of nontuberculous mycobacteria (NTM) disease.
RedHill (RDHL) COVID-19 Drug Shows Promise in Mid-Stage Study
by Zacks Equity Research
RedHill's (RDHL) opaganib achieves greater improvement in reducing oxygen requirement compared to placebo in a phase II study evaluating it in patients hospitalized with COVID-19 pneumonia.
Is the Options Market Predicting a Spike in RedHill Biopharma (RDHL) Stock?
by Zacks Equity Research
Investors need to pay close attention to RedHill Biopharma (RDHL) stock based on the movements in the options market lately.
RedHill (RDHL) Expands Opaganib Manufacturing Capacity in US
by Zacks Equity Research
RedHill (RDHL) expands its manufacturing capacity to support the potential emergency use applications to be filed for opaganib to address severe COVID-19 pneumonia in the United States.
RedHill (RDHL) to Begin Study on Second Coronavirus Candidate
by Zacks Equity Research
The FDA clears RedHill's (RDHL) IND filing for a phase II/III study on its second coronavirus candidate RHB-107 to treat patients with symptomatic COVID-19 who do not require hospitalization.
RedHill (RDHL) Closes Enrollment for Phase II Coronavirus Study
by Zacks Equity Research
Redhill (RDHL) completes enrollment in the phase II study on opaganib in patients hospitalized with severe COVID-19 pneumonia.
RedHill's (RDHL) RHB-204 Gets FDA Orphan Drug Designation
by Zacks Equity Research
RedHill (RDHL) gets Orphan Drug status from the FDA for the treatment of nontuberculous mycobacteria (NTM) disease.
RedHill Gets Nod in Brazil for Coronavirus Study on Opaganib
by Zacks Equity Research
The Brazilian Health Regulatory Agency okays RedHill's (RDHL) to conduct a phase II/III study on opaganib for treating patients with severe COVID-19 infection and pneumonia. Stock up.
RedHill (RDHL) to Study Opaganib for Severe Coronavirus in UK
by Zacks Equity Research
RedHill's (RDHL) CTA gets approval in the United Kingdom to start a phase II/III study on opaganib for patients hospitalized with severe COVID-19 infection and pneumonia.
RedHill Files CTA for Coronavirus Study on Opaganib in Russia
by Zacks Equity Research
RedHill (RDHL) submits a Clinical Trial Application in Russia for a phase II/III study on opaganib to treat patients detected with severe COVID-19 infection and pneumonia. Stock up.
Is Redhill Biopharma (RDHL) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (RDHL) Outperforming Other Medical Stocks This Year?
Is Redhill Biopharma (RDHL) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (RDHL) Outperforming Other Medical Stocks This Year?
RedHill's Oncology Candidate to be Tested for Coronavirus
by Zacks Equity Research
RedHill (RDHL) inks a deal with NIAID for non-clinical testing of its investigational candidate RHB-107 to evaluate its activity against COVID-19. Stock up.
RedHill (RDHL) Soars: Stock Adds 9.2% in Session
by Zacks Equity Research
RedHill (RDHL) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.
Top Ranked Momentum Stocks to Buy for April 9th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, April 9th
Top Ranked Momentum Stocks to Buy for April 7th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, April 7th